June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego)

BOCA RATON, FLORIDA & STOCKHOLM, SWEDEN – June 4, 2026 – Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers.

Vycellix is attending:
June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo
June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm
June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319)
To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.com.

Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC) with rigorous studies across many donor cell types proving robust immune evasion with functional persistence. The Company is now preparing for first-in-human clinical validation by seeking regulatory approval in Sweden to initiate a Phase 1 study for its lead VY-UC product candidate, a novel, off-the-shelf NK cell therapy (VNK-101) for patients with relapsed or refractory multiple myeloma.

To view VY-UC mechanism-of-action video, please visit:
https://vycellix.com/universal-cells-2026/

The Company has also generated new data in AML and urothelial cancers supporting further development of its VY-GAGE platform and product candidates to engineer persistent allogeneic effector cells capable of delivering multiple disease-targeting payloads directly to tumor sites using logic-gated CARs and proprietary cleavable linkers, which when tumor-activated, deploy potent multi-antigen engagers, CARs and cytokines. This approach is believed to be safer with optimized target engagement and https://vycellix.com/tumor-activated-engagers/more effective by limiting cytotoxic killing to only occur within the solid tumor microenvironment.

To view VY-GAGE mechanism-of-action video, please visit:
https://vycellix.com/tumor-activated-engagers/

About Vycellix, Inc.
With dual headquarters Florida and Sweden, Vycellix is a biotechnology cell therapy company with the mission to deliver superior outcomes for patients through the delivery of highly innovative allogeneic medicines that eliminate the risk of immune rejection to confer functional persistence with therapeutic durability.

The Company is redefining off-the-shelf, donor-cell-based treatment strategies by leveraging its two transformational platforms: 1) VY-UC, a single-engineering-step CD45 engager that prevents immune rejection of grafted cells while preserving donor cell viability, fitness, function with persistence, and 2) VY-GAGE, a first-in-class cell therapy that consolidates multi-modal immunotherapies into a single tumor-directed therapy expected to minimize “on-target, off-tumor” adverse events, while optimizing target engagement.

Vycellix’s foundational science was developed at Sweden’s Karolinska Institutet and the Company is a partner in ‘NextGenNK’, Sweden’s Innovation Agency’s Competence Center focused on the development of next-generation NK cell therapies.


For more information, please visit: www.Vycellix.com